Association of Lipids, Lipoproteins, and Apolipoproteins with Stroke Subtypes in an International Case Control Study (INTERSTROKE).
Apolipoproteins
Case-control
Dyslipidemia
Lipoproteins
Risk factor
Stroke
Journal
Journal of stroke
ISSN: 2287-6391
Titre abrégé: J Stroke
Pays: Korea (South)
ID NLM: 101602023
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
16
06
2022
accepted:
11
04
2022
entrez:
9
6
2022
pubmed:
10
6
2022
medline:
10
6
2022
Statut:
ppublish
Résumé
The association of dyslipidemia with stroke has been inconsistent, which may be due to differing associations within etiological stroke subtypes. We sought to determine the association of lipoproteins and apolipoproteins within stroke subtypes. Standardized incident case-control STROKE study in 32 countries. Cases were patients with acute hospitalized first stroke, and matched by age, sex and site to controls. Concentrations of total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A1 (apoA1), and apoB were measured. Non-HDL-C was calculated. We estimated multivariable odds ratio (OR) and population attributable risk percentage (PAR%). Outcome measures were all stroke, ischemic stroke (and subtypes), and intracerebral hemorrhage (ICH). Our analysis included 11,898 matched case-control pairs; 77.3% with ischemic stroke and 22.7% with ICH. Increasing apoB (OR, 1.10; 95% confidence interval [CI], 1.06 to 1.14 per standard deviation [SD]) and LDL-C (OR, 1.06; 95% CI, 1.02 to 1.10 per SD) were associated with an increase in risk of ischemic stroke, but a reduced risk of ICH. Increased apoB was significantly associated with large vessel stroke (PAR 13.4%; 95% CI, 5.6 to 28.4) and stroke of undetermined cause. Higher HDL-C (OR, 0.75; 95% CI, 0.72 to 0.78 per SD) and apoA1 (OR, 0.63; 95% CI, 0.61 to 0.66 per SD) were associated with ischemic stroke (and subtypes). While increasing HDL-C was associated with an increased risk of ICH (OR, 1.20; 95% CI, 1.14 to 1.27 per SD), apoA1 was associated with a reduced risk (OR, 0.80; 95% CI, 0.75 to 0.85 per SD). ApoB/A1 (OR, 1.38; 95% CI, 1.32 to 1.44 per SD) had a stronger magnitude of association than the ratio of LDL-C/HDL-C (OR, 1.26; 95% CI, 1.21 to 1.31 per SD) with ischemic stroke (P<0.0001). The pattern and magnitude of association of lipoproteins and apolipoproteins with stroke varies by etiological stroke subtype. While the directions of association for LDL, HDL, and apoB were opposing for ischemic stroke and ICH, apoA1 was associated with a reduction in both ischemic stroke and ICH. The ratio of apoB/A1 was the best lipid predictor of ischemic stroke risk.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
The association of dyslipidemia with stroke has been inconsistent, which may be due to differing associations within etiological stroke subtypes. We sought to determine the association of lipoproteins and apolipoproteins within stroke subtypes.
METHODS
METHODS
Standardized incident case-control STROKE study in 32 countries. Cases were patients with acute hospitalized first stroke, and matched by age, sex and site to controls. Concentrations of total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A1 (apoA1), and apoB were measured. Non-HDL-C was calculated. We estimated multivariable odds ratio (OR) and population attributable risk percentage (PAR%). Outcome measures were all stroke, ischemic stroke (and subtypes), and intracerebral hemorrhage (ICH).
RESULTS
RESULTS
Our analysis included 11,898 matched case-control pairs; 77.3% with ischemic stroke and 22.7% with ICH. Increasing apoB (OR, 1.10; 95% confidence interval [CI], 1.06 to 1.14 per standard deviation [SD]) and LDL-C (OR, 1.06; 95% CI, 1.02 to 1.10 per SD) were associated with an increase in risk of ischemic stroke, but a reduced risk of ICH. Increased apoB was significantly associated with large vessel stroke (PAR 13.4%; 95% CI, 5.6 to 28.4) and stroke of undetermined cause. Higher HDL-C (OR, 0.75; 95% CI, 0.72 to 0.78 per SD) and apoA1 (OR, 0.63; 95% CI, 0.61 to 0.66 per SD) were associated with ischemic stroke (and subtypes). While increasing HDL-C was associated with an increased risk of ICH (OR, 1.20; 95% CI, 1.14 to 1.27 per SD), apoA1 was associated with a reduced risk (OR, 0.80; 95% CI, 0.75 to 0.85 per SD). ApoB/A1 (OR, 1.38; 95% CI, 1.32 to 1.44 per SD) had a stronger magnitude of association than the ratio of LDL-C/HDL-C (OR, 1.26; 95% CI, 1.21 to 1.31 per SD) with ischemic stroke (P<0.0001).
CONCLUSIONS
CONCLUSIONS
The pattern and magnitude of association of lipoproteins and apolipoproteins with stroke varies by etiological stroke subtype. While the directions of association for LDL, HDL, and apoB were opposing for ischemic stroke and ICH, apoA1 was associated with a reduction in both ischemic stroke and ICH. The ratio of apoB/A1 was the best lipid predictor of ischemic stroke risk.
Identifiants
pubmed: 35677977
pii: jos.2021.02152
doi: 10.5853/jos.2021.02152
pmc: PMC9194539
doi:
Types de publication
Journal Article
Langues
eng
Pagination
224-235Subventions
Organisme : CIHR
Pays : Canada
Organisme : Heart and Stroke Foundation of Canada
Organisme : Canadian Stroke Network
Organisme : Swedish Research Council
Organisme : Swedish Heart and Lung Foundation
Organisme : The Health & Medical Care Committee of the Regional Executive Board
Organisme : Region Vastra Gotaland
Organisme : AstraZeneca
Organisme : Boehringer Ingelheim
Organisme : Pfizer Canada
Organisme : MSD
Organisme : Swedish Heart and Lung Foundation
Organisme : Chest, Heart and Stroke Scotland
Organisme : The Stroke Association
Organisme : The UK-Stroke Research Network
Références
J Intern Med. 2006 Mar;259(3):259-66
pubmed: 16476103
N Engl J Med. 2006 Aug 10;355(6):549-59
pubmed: 16899775
Lancet. 2016 Aug 20;388(10046):761-75
pubmed: 27431356
Stroke. 2004 Jun;35(6):1524-5
pubmed: 15105510
Stroke. 2012 Apr;43(4):958-66
pubmed: 22308251
Ann Neurol. 2016 Nov;80(5):730-740
pubmed: 27717122
Lancet. 2020 Nov 21;396(10263):1644-1652
pubmed: 33186534
Atherosclerosis. 2014 Apr;233(2):343-348
pubmed: 24530960
Ann Intern Med. 2011 Dec 6;155(11):742-50
pubmed: 22147713
Alzheimers Res Ther. 2019 May 13;11(1):44
pubmed: 31084613
PLoS One. 2016 Mar 02;11(3):e0149605
pubmed: 26934734
Cerebrovasc Dis. 2006;21(5-6):323-8
pubmed: 16490941
Neurology. 2008 Mar 11;70(11):841-7
pubmed: 18160673
JAMA. 2009 Nov 11;302(18):1993-2000
pubmed: 19903920
Lancet. 1991 Jun 22;337(8756):1521-6
pubmed: 1675378
Lipids Health Dis. 2016 Mar 01;15:43
pubmed: 26932585
J Neurol Neurosurg Psychiatry. 2000 May;68(5):558-62
pubmed: 10766882
Diabetes Care. 2017 Apr;40(4):529-537
pubmed: 28122840
Biometrics. 1990 Dec;46(4):991-1003
pubmed: 2085643
Eur J Epidemiol. 2007;22(12):839-69
pubmed: 17876711
J Neurol Sci. 2004 May 15;220(1-2):55-8
pubmed: 15140606
Lancet. 2007 Dec 1;370(9602):1829-39
pubmed: 18061058
Neurology. 2015 Feb 3;84(5):472-9
pubmed: 25568296
Curr Opin Endocrinol Diabetes Obes. 2017 Apr;24(2):148-153
pubmed: 28099205
N Engl J Med. 2007 Nov 22;357(21):2109-22
pubmed: 17984165
Am Fam Physician. 2014 Apr 15;89(8):Online
pubmed: 24784129
Neurology. 2008 Apr 1;70(14):1208-14
pubmed: 18378884
Int J Stroke. 2014 Oct;9 Suppl A100:119-26
pubmed: 25088494
N Engl J Med. 2016 May 26;374(21):2021-31
pubmed: 27040132
Circ Genom Precis Med. 2019 Dec;12(12):e002711
pubmed: 31756303
Neuroepidemiology. 2010;35(1):36-44
pubmed: 20389123
Stroke. 2018 Apr;49(4):820-827
pubmed: 29535274
Stroke. 1988 Dec;19(12):1497-500
pubmed: 3201508
J Am Coll Cardiol. 2016 Nov 8;68(19):2073-2083
pubmed: 27810046
EBioMedicine. 2015 Aug 06;2(9):1071-8
pubmed: 26501105
Bull World Health Organ. 1976;54(5):541-53
pubmed: 1088404
Arch Neurol. 2009 Nov;66(11):1400-6
pubmed: 19901173
Lancet. 2004 Mar 6;363(9411):757-67
pubmed: 15016485
N Engl J Med. 2020 Jan 2;382(1):9
pubmed: 31738483
J Am Coll Cardiol. 2018 Feb 13;71(6):620-632
pubmed: 29420958
Stroke. 2013 Jul;44(7):1833-9
pubmed: 23704101
Geriatr Gerontol Int. 2012 Apr;12 Suppl 1:18-28
pubmed: 22435937
Lancet. 2019 Dec 14;394(10215):2173-2183
pubmed: 31810609
Am J Cardiol. 2016 Sep 15;118(6):804-810
pubmed: 27471056
Stroke. 2005 Jan;36(1):56-61
pubmed: 15569873
Int J Cardiol. 2016 Nov 1;222:548-556
pubmed: 27513651
J Atheroscler Thromb. 2011;18(2):89-98
pubmed: 20972352
Int J Cardiol. 2016 Oct 1;220:890-4
pubmed: 27400190
J Intern Med. 2009 Feb;265(2):275-87
pubmed: 19019184
Int J Cardiol. 2016 Oct 1;220:262-7
pubmed: 27389451
Neurology. 2007 Feb 20;68(8):556-62
pubmed: 17310025
J Biomed Res. 2017 May 26;:
pubmed: 28550271
Acta Neurol Belg. 2004 Mar;104(1):13-9
pubmed: 15143957
Neurol Res. 2013 Jun;35(5):505-11
pubmed: 23594748
Arterioscler Thromb Vasc Biol. 2016 Sep;36(9):2004-10
pubmed: 27444203
Stroke. 1993 Jan;24(1):35-41
pubmed: 7678184
Lancet. 2004 Sep 11-17;364(9438):937-52
pubmed: 15364185